{"groups":[{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Ramucirumab administered intravenously at a dose of 12 milligrams per kilogram (mg/kg) as a one-hour infusion on days 1 and 15.\n* Cyclophosphamide administered orally at 25 milligrams per meter square (mg/m2) daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"FG000","title":"Ramucirumab + Cyclophosphamide + Vinorelbine"},{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"FG001","title":"Cyclophosphamide + Vinorelbine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"10"}],"type":"Received at Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"7"}],"comment":"Completers included participants who died due to any cause or were alive and on study at conclusion but off treatment.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}